JP2003528826A5 - - Google Patents

Download PDF

Info

Publication number
JP2003528826A5
JP2003528826A5 JP2001562556A JP2001562556A JP2003528826A5 JP 2003528826 A5 JP2003528826 A5 JP 2003528826A5 JP 2001562556 A JP2001562556 A JP 2001562556A JP 2001562556 A JP2001562556 A JP 2001562556A JP 2003528826 A5 JP2003528826 A5 JP 2003528826A5
Authority
JP
Japan
Prior art keywords
compound according
gly
preparation
arrhythmia
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001562556A
Other languages
English (en)
Other versions
JP2003528826A (ja
JP4327398B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2001/000127 external-priority patent/WO2001062775A2/en
Publication of JP2003528826A publication Critical patent/JP2003528826A/ja
Publication of JP2003528826A5 publication Critical patent/JP2003528826A5/ja
Application granted granted Critical
Publication of JP4327398B2 publication Critical patent/JP4327398B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】式I:X−(Y’)−(Px)−G’−A−(G’)−R
[式中、全てのアミノ酸残基は独立にD型であり、
XはHまたはAcを表し;
G’はグリシン残基またはSarを表し;
Aはアラニンを表し;
Pxは式IIのアミノ酸残基を表し;
【化1】
Figure 2003528826
{式中、nは3、4、または5を有する整数であり、Rは任意の置換基を表し}
Y’はハロゲンまたはヒドロキシでフェニル環において任意に置換されたチロシンまたはフェニルアラニンを表し;
a及びbは独立に0または1であり;
はOH、NH、NHNH、Asn−NH、またはGln−NHを表す]
を有する化合物及びその製薬学的に許容可能な塩。
【請求項2】Pxが3Hyp、4Hyp、またはProのアミノ酸残基を表す、請求項1に記載の化合物。
【請求項3】Ac−D−Tyr−D−Pro−D−Hyp−Gly−D−Ala−Gly−OH;
Ac−D−Tyr−D−Pro−D−4Hyp−Gly−D−Ala−Gly−NH(化合物2)
からなる群から選択された、請求項1または2に記載の化合物およびその製薬学的に許容可能な塩。
【請求項4】請求項1から3のいずれか一項に記載の化合物、及び製薬学的に許容可能な担体または希釈液を含む製薬組成物。
【請求項5】注射調製物である、請求項4に記載の組成物。
【請求項6】不整脈の治療用医薬の調製のための、請求項1から3のいずれか一項に記載の化合物の使用。
【請求項7】前記不整脈が心房細動、心室細動、または房室ブロックである、請求項6に記載の使用。
【請求項8】前記不整脈が徐脈不整脈である、請求項6に記載の使用。
【請求項9】前記不整脈が頻拍不整脈である、請求項7に記載の使用。
【請求項10】前記頻拍不整脈が心室頻拍である、請求項9に記載の使用。
【請求項11】収縮減少の治療用医薬の調製のための、請求項1から3のいずれか一項に記載の化合物の使用。
【請求項12】T波交代を有する患者の治療用医薬の調製のための、請求項1から3のいずれか一項に記載の化合物の使用。
JP2001562556A 2000-02-23 2001-02-22 新規な抗不整脈性ペプチド Expired - Fee Related JP4327398B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK200000288 2000-02-23
DKPA200000288 2000-02-23
DKPA200000738 2000-05-04
DK200000738 2000-05-04
PCT/DK2001/000127 WO2001062775A2 (en) 2000-02-23 2001-02-22 Novel antiarrhythmic peptides

Publications (3)

Publication Number Publication Date
JP2003528826A JP2003528826A (ja) 2003-09-30
JP2003528826A5 true JP2003528826A5 (ja) 2006-02-16
JP4327398B2 JP4327398B2 (ja) 2009-09-09

Family

ID=26068776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001562556A Expired - Fee Related JP4327398B2 (ja) 2000-02-23 2001-02-22 新規な抗不整脈性ペプチド

Country Status (10)

Country Link
EP (1) EP1226160B1 (ja)
JP (1) JP4327398B2 (ja)
AT (1) ATE284896T1 (ja)
AU (1) AU781674B2 (ja)
CA (1) CA2385659C (ja)
DE (1) DE60107803T2 (ja)
ES (1) ES2228807T3 (ja)
PT (1) PT1226160E (ja)
WO (1) WO2001062775A2 (ja)
ZA (1) ZA200306410B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585839B2 (en) 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
WO2002077017A2 (en) * 2001-02-22 2002-10-03 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
KR20040094677A (ko) * 2002-01-29 2004-11-10 와이어쓰 코넥신 헤미채널 조절을 위한 조성물 및 방법
BR0316488A (pt) * 2002-11-25 2005-10-11 Zealand Pharma As Métodos para modular uma comunicação de junção lacunar em uma população de células, e para tratar um paciente tendo ou sob risco de desenvolver uma condição patológica envolvendo comunicação de junção lacunar deficiente, uso de um peptìdeo, e, composição farmacêutica
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
EP1725555B1 (en) 2004-03-08 2010-10-06 Prosidion Ltd. Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
GB0514071D0 (en) 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
PT1966130E (pt) 2005-12-23 2014-01-30 Zealand Pharma As Compostos miméticos de lisina modificados
US20080188545A1 (en) 2006-12-21 2008-08-07 Alimardanov Asaf R Synthesis of pyrrolidine compounds
EP2260859A1 (en) 2009-06-12 2010-12-15 Zealand Pharma A/S Compounds acting as peptide gap junction modulators and their uses
WO2014049540A2 (en) 2012-09-29 2014-04-03 Novartis Ag Cyclic peptides and use as medicines
CN103113456B (zh) * 2013-03-05 2014-07-16 中国药科大学 具有抗血小板聚集活性的僵蚕多肽及其制备方法和应用
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6259296A (ja) * 1985-09-10 1987-03-14 Green Cross Corp:The ペプタイド誘導体
DE19500990A1 (de) * 1995-01-14 1996-07-18 Stefan Dr Med Dhein Neues Peptid, seine Herstellung und Verwendung
DE19707854A1 (de) * 1997-02-27 1998-09-03 Dhein Stefan Priv Doz Dr Med Neue Cyclopeptide, deren Herstellung und Verwendung

Similar Documents

Publication Publication Date Title
JP2003528826A5 (ja)
JP2021100937A5 (ja)
EP1159964A3 (en) Compositions and methods for stimulating gastrointestinal motility
CY1106482T1 (el) Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
JP2004534850A5 (ja)
JP2005523922A5 (ja)
JP2002525323A5 (ja)
MXPA04005906A (es) Cis-2,4,5-trifenil-.imidazolinas y uso de la misma para tratamiento de tumores.
JP2003522198A5 (ja)
JP2008530975A5 (ja)
JP2004503564A5 (ja)
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
ES2387249T3 (es) Poliamidas para el tratamiento del virus del papiloma humano
JP2002275067A (ja) 抗虚血薬剤
DE69327642D1 (de) Verfahren zur behandlung von viralen infectionen
EP1184035A3 (en) Use of growth hormone secretagogues for treatment of physical performance decline
ES2122015T3 (es) Uso de urodilatina en enfermedades pulmonares y bronquiales.
JP2006514104A5 (ja)
JP2006527185A5 (ja)
WO2004029064A8 (en) (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof
JP2003522185A5 (ja)
JP2004538314A5 (ja)
JP2002533385A (ja) 感染症の予防及び治療へのビスホスホネートの使用
RU2002102076A (ru) Фармацевтическая композиция, содержащая сибутрамин и орлистат
JP2004526702A5 (ja)